Helicobacter hepaticus infection in BALB/c mice abolishes subunit-vaccine-induced protection against M. tuberculosis  by Arnold, Isabelle C. et al.
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a  b  s  t  r  a  c  t
BCG,  the only  licensed  vaccine  against  tuberculosis  (TB),  provides  geographically  variable  protection,
an  effect  ascribed  to exposure  to environmental  mycobacteria  (EM).  Here  we  show  that  altering  the
intestinal  microbiota  of  mice  by early-life  infection  with  the  commensal  bacterium  Helicobacter  hepaticus
(Hh)  increases  their  susceptibility  to challenge  with  Mycobacterium  tuberculosis  (Mtb).  Furthermore  Hh-
infected  mice  immunised  parenterally  with  the  recombinant  subunit  vaccine,  human  adenovirus  type  5
expressing  the immunodominant  antigen  85A  of  Mtb  (Ad85A),  display  a reduced  lung  immune  response
and  protection  against  Mtb  challenge  is  also  reduced.  Expression  of  interleukin  10 (IL10)  messenger  RNAubunit vaccine
uberculosis
nterleukin 10
is increased  in  the colon  of  Hh  infected  mice.  Treatment  of  Hh-infected  Ad85A-immunised  mice  with  anti-
IL10  receptor  antibody,  following  challenge  with  Mtb,  restores  the protective  effect  of the  vaccine. These
data  show  for  the  ﬁrst  time  that  alteration  of  the  intestinal  microbiota  by addition  of  a single  commensal
organism  can  profoundly  inﬂuence  protection  induced  by a TB  subunit  vaccine  via an  IL10-dependent
mechanism,  a result  with  implications  for  the  deployment  of  such  vaccines  in  the  ﬁeld.
Crown  Copyright  © 2015  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC. Introduction
Tuberculosis (TB) is an important cause of morbidity and mor-
ality worldwide with nearly 9 million new infections annually and
.4 million deaths. The difﬁculty of reducing this disease burden is
ompounded by the spread of drug resistant organisms and the
reatly increased susceptibility of HIV patients to TB [1].
In the face of these problems, vaccination is an attractive strat-
gy but the protective efﬁcacy of the only licensed vaccine, BCG,
aries geographically and wanes with time. Furthermore, boost-
ng with BCG is generally ineffective [2]. This has led to attempts
ither to replace BCG with a more effective vaccine or to improve
ts efﬁcacy with booster vaccines.
Abbreviations: Hh, Helicobacter hepaticus; Mtb, Mycobcterium tuberculosis; CFU,
olony forming units.
∗ Corresponding author. Present address: The Pirbright Institute, Ash Road, Pir-
right, Surrey, UK. Tel.: +44 0 483231410.
E-mail address: elma.tchilian@pirbright.ac.uk (E. Tchilian).
1 Present address: Respiratory Infection and Airway Disease Infection Section,
ational Heart & Lung Institute (NHLI), Imperial College London, London, UK.
ttp://dx.doi.org/10.1016/j.vaccine.2015.02.041
264-410X/Crown Copyright © 2015 Published by Elsevier Ltd. This is an open 
icenses/by-nc-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A common hypothesis to account for the variation in BCG effec-
tiveness in different locations is that this is due to environmental
effects, including exposure to environmental mycobacteria (EM),
which might may  prevent growth of BCG, mask BCG-induced
protection or induce regulatory T cells, as demonstrated exper-
imentally in mice [3]. Clearly if subunit booster vaccines are to
be used to improve the efﬁcacy of BCG, it will be important to
know whether their efﬁcacy is similarly subject to environmental
inﬂuences. In fact, when EM are administered orally and a subunit
vaccine parenterally, protection against Mtb challenge is reduced
[4]. However, in these experiments large quantities of EM were con-
tinuously administered in the drinking water, so that the question
remained whether less artiﬁcial changes in the microbiota of the
intestine might also inﬂuence protective immune responses to a
subunit TB vaccine.
Multiple studies have highlighted the immunomodulatory
effect of enteric microorganism exposure on lung immune
responses. Experimental helminth infection in mice has been
shown to impair innate pulmonary host defence against Mtb
through the IL4 receptor signalling pathway [5] and helminth infec-
tion has been associated with increased TB incidence and reduced
BCG vaccine efﬁcacy in affected populations [6]. In contrast,
access article under the CC BY-NC-ND license (http://creativecommons.org/
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pidemiological evidence suggests that infection with the gastric
acterium Helicobacter pylori is associated with protection against
B [7], while neonatal infection of mice with H. pylori prevents the
nduction of allergic lung disease later in life [8].
The related gram-negative bacterium, Helicobacter hepaticus
Hh), is a non-invasive organism commonly found in the murine
ower intestinal tract in mouse colonies [9]. Hh does not cause his-
ological lesions in immunocompetent mice but IL10 insufﬁcient
ice develop typhlocolitis [10]. Inﬂammation develops via induc-
ion of Th17 cells in the intestinal mucosa that rapidly extinguish
L17A production and become IFN producing Th1 cells [10–12].
In these experiments, we investigate the effect of Hh on immune
esponse and protection induced by the recombinant subunit vac-
ine, human adenovirus type 5 expressing the immunodominant
ntigen 85A of Mtb  (Ad85A) [13].
. Materials and methods
.1. Mice
All experiments were performed with BALB/c mice bred in
ouse. Sentinel mice were screened every 3 months by Harlan Orlac
Blackthorn, UK) to exclude the presence of Helicobacter species and
reeders were replaced after every experimental Hh infection. The
xperiments were approved by the animal use ethical committee
f Oxford University and complied with UK Home Ofﬁce guidelines.
.2. Hh infection and quantitation
Hh NCI-Frederick isolate 1A (strain 51449) was grown as
escribed previously [14]. Seven day old BALB/c mice from
elicobacter-free breeders were fed on two consecutive days with
h 1A (∼2.5 × 107 CFU) by oral gavage. Hh colonisation was ana-
yzed in caecal contents collected upon sacriﬁce. DNA was isolated
sing the DNA Stool kit (QIAGEN) and SYBR Green real-time PCR
ith Hh-speciﬁc primers against the cdtB gene (Fwd: CCG CAA ATT
CA GCA ATA CTT; Rev: TCG TCC AAA ATG CAC AGG TG) was  per-
ormed in triplicate using the CFX96 detection system (Bio-Rad
aboratories). Results represent arbitrary units normalised to unin-
ected control samples.
.3. Ad85A immunisation
Four to ﬁve weeks after Hh administration, infected and
atched control mice were immunised with 2 × 109 virus particles
f Ad85A equally divided between the two quadriceps muscles.
.4. Infection with Mtb  and determination of mycobacterial load
Five to ten mice were anesthetised with isoﬂurane and infected
.n. with Mtb  (Erdman strain) in 40 l PBS. The number of organisms
eposited was determined 24 h after challenge (∼200 CFU). Mice
ere sacriﬁced 5 weeks post-challenge. Lungs were homogenised
nd 10-fold serial dilutions of tissue homogenates were plated on
iddlebrook 7H11 agar plates (E&O Laboratories Ltd, Bonnybridge,
K) to determine mycobacterial load. Colony-forming units (CFU)
ere enumerated after 3–4 weeks of incubation at 37 ◦C in 5% CO2..5. Treatment with antibody to the IL-10 receptor
Naive or Hh infected mice were immunised with Ad85A i.m.
r left unimmunised. Following challenge with Mtb, mice were
njected intraperitoneally on day 0, 7 and 17 with 1 mg  of anti-
L-10R antibody (clone 1B1.2) or PBS as control.3 (2015) 1808–1814 1809
2.6. Histopathological assessment
Five weeks after Mtb challenge, lungs from infected mice were
removed and ﬁxed in buffered 4% formalin. 4–5 m parafﬁn-
embedded sections were stained with haematoxylin and eosin, and
histopathology of the lungs was  assessed semi-quantitatively in a
blinded fashion by a trained pathologist.
2.7. Isolation of lymphocytes from lungs, spleen, gut and MLN
Lungs were perfused with PBS, cut into pieces and digested with
0.7 mg/ml  collagenase type I (Sigma) and 30 g/ml DNase I (Sigma)
for 45 min  at 37 ◦C. Digested fragments were crushed through a
cell strainer using a syringe plunger, washed with PBS, layered
over Lympholyte (Cederlane, Ontario, Canada) and centrifuged at
1000 × g for 25 min. Interface cells were collected and washed.
Spleens and MLNs cell suspensions were prepared by mashing the
tissue through a cell strainer using a syringe plunger. For spleens,
red blood cells were removed with lysis buffer (Qiagen, Crawley,
UK) and the cells were washed with PBS. For colonic lamina pro-
pria cell isolation, colons were opened longitudinally, washed in
PBS 0.1% BSA and cut into pieces. Pieces were washed twice in HBSS
supplemented with 4% FBS, 100 U/ml penicillin/streptomycin and
5 mM EDTA at 37 ◦C with shaking to remove epithelial cells. Tissue
was then digested at 37 ◦C in a shaking incubator with 1 mg/ml
type VIII collagenase (Sigma-Aldrich) and 0.5 mg/ml DNase I in
RPMI-1640 medium supplemented with 4% FBS and 100 U/ml peni-
cillin/streptomycin. The isolated cells were layered on a 40/80%
Percoll gradient and the interface was collected and washed.
2.8. Flow cytometry
For surface staining, cells were washed and incubated with
CD16/CD32 monoclonal antibody to block Fc binding. Cells were
stained with a ﬁxable viability dye and a combination of the fol-
lowing antibodies: CD45 (30-F11), CD3 (17A2), CD4 (RM4-5), CD8
(53-6.7), CD44 (IM7), CD62L (MEL-14) and CD25 (PC61.5) surface
markers. For Tregs staining, cells were ﬁxed and permeabilised with
the Foxp3/Transcription Factor Staining Buffer Set (eBioscience)
according to the manufacturer’s instructions and stained with
Foxp3 (FJK-16s). For intracellular cytokine staining in response to
85A stimulation, cells from Ad85A immunised animals were stim-
ulated for 6 h with a pool of 66 15-mer peptides overlapping by
10 amino acids, covering the 85A protein sequence (Peptide Pro-
tein Research Ltd, Fareham, UK), in Hepes buffered RPMI with
10% heat-inactivated FCS, l-glutamine, penicillin and streptomycin.
Each peptide was 2 at g/ml. After 2 h at 37 ◦C, Golgi Plug (BD
Biosciences, Oxford, UK) was  added according to the manufac-
turer’s instructions. Cells were stained for surface markers then for
intracellular IFN (XMG1.2) and TNF (MP6-XT22) (eBioscience,
Hatﬁeld, UK) using the BD Cytoﬁx/Cytoperm kit according to the
manufacturer’s instructions. All cells were run on a LSRII (BD
Biosciences) and analysed using FlowJo software (Tree Star Inc,
Ashland, Oregon, USA).
2.9. Quantitation of gene expression using TaqMan qPCR
RNA was  isolated from snap-frozen lung and colonic tissue using
the RNeasy Mini kit (QIAGEN) according to the manufacturer’s
instructions, including an on-column DNase I digestion step. cDNA
synthesis was  performed using the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). Quantitative real-time PCR
(qRT-PCR) for the candidate genes was performed using TaqMan
gene expression assays (Life Technologies). cDNA samples were
analysed in duplicate using the CFX96 detection system (Bio-Rad
Laboratories) and values were normalised to Hprt according to the
1810 I.C. Arnold et al. / Vaccine 33 (2015) 1808–1814
Fig. 1. Protection against Mtb  challenge. BALB/c mice were infected with Hh and
5  weeks later immunised with 2 × 109 v.p. Ad85A i.m. Controls were uninfected
naïve or uninfected Ad85A immunised animals. Mice were challenged with Mtb
5  weeks after immunisation and lung Mtb  CFU were determined 5 weeks after
challenge. (A) Schematic depiction of the treatment regimen. (B) Lung Mtb CFU.
Symbols show individual mice and horizontal lines indicate the mean. *** p < 0.001,
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Fig. 2. Histopathology. (A) Representative histopathology of the lungs of mice 5
weeks after Mtb challenge. Naïve mice are compared to the lungs of mice immu-
nised with Ad85A or mice infected with Hh or infected with Hh and immunisd
with Ad85A. Haematoxylin/eosin-stained parafﬁn-embedded lung sections. Bar is
100 m.  (B) Histograms show mean and standard error of semi-quantitative scoring*  p < 0.01 between the indicated groups as determined by one-way ANOVA with
ukey’s post-test. Data are representative of two  independent experiments with
imilar results.
-Ct method. TaqMan Gene Expression Assays were performed
or mouse Hprt (Mm01545399 m1), Il10 (Mm00439614 ml),
bx21 (Mm00450960 m1), Gata3 (Mm00484683 m1), Rorc
Mm01261022 m1)  and Foxp3 (Mm00475162 m1).
.10. Statistical analysis
Data were analysed using one-way ANOVA followed by Tukey’s
ultiple comparison tests. Immune responses and histopatholog-
cal scores were assessed by Mann–Whitney U with Bonferroni’s
ost-test.
. Results
.1. Hh infection increases Mtb  bacterial load and abolishes the
rotective effect of Ad85A immunisation
In order to understand how early life exposure to a bacterial
rigger could inﬂuence the response to Mtb  infection and vac-
ine efﬁcacy, we assessed the impact of neonatal infection with
h on Mtb  challenge in mice. One week old BALB/C mice were
nfected with Hh orally and challenged intranasally at ten weeks
f age with Mtb  along with uninfected littermates. Mice were
ssessed for mycobacterial load in the lungs 5 weeks post-challenge
Fig. 1A). We  observed that Hh infected animals had an average
.6 log increase of Mtb  CFU in the lungs compared to their unin-
ected littermates (Fig. 1B).Similarly, groups of Hh infected or uninfected mice were immu-
ised with Ad85A at weeks 6 of age and challenged 5 weeks
ater with Mtb  (Fig. 1A). As previously reported, Ad85A immun-
sation efﬁciently reduced the Mtb  colonisation level in the lungs ofof  the extent of pathology in groups of 10 mice as 10–15%, 15–25%, 25–50%, 50–70%
and >70%. ** p < 0.01, * p < 0.05 between the indicated groups by Mann Whitney U
test.
uninfected mice by ∼0.5 log10 [4]. However, early-life infection
with Hh strikingly abolished the protective effect of Ad85A (Fig. 1B).
Histological analysis shows that naive mice have multifocal
coalescing granulomatous lesions composed of macrophages and
lymphocytes with small aggregates of neutrophils and scattered
multinucleate cells, making up 50–70% of the sections in most
animals (Fig. 2A). In contrast, Ad85A immunised mice show sig-
niﬁcantly smaller areas of interstitial inﬂammation with a low
number of lymphohistiocytic aggregates (Fig. 2B). Lungs from Hh-
infected animals show multifocal lesions with mild interstitial
inﬁltrates and foci of peribronchial lymphocytes, often with focal
extravasated red blood cells (haemorrhage), mild oedema and con-
gestion. Interestingly, the pathological appearance in Hh-infected
animals immunised with Ad85A is similar to their non-immunised
counterparts, but in several animals the inﬂammation is severe,
with intra-alveolar inﬂammatory inﬁltrates in addition to areas
of haemorrhage and oedema. Thus, the histopathological appear-
ances reﬂect the abolition of the protective effect of Ad85A by Hh
infection.
3.2. Effect of Hh infection on antigen speciﬁc responses and lung
cell compositionTo characterise in more detail the effect of Hh infection on
Ad85A immunisation, we measured 85A-speciﬁc responses in the
lungs and spleen 4–5 weeks after immunisation, at the peak of
the response to Ad85A. Intramuscular administration of Ad85A has
I.C. Arnold et al. / Vaccine 33 (2015) 1808–1814 1811
Fig. 3. Antigen 85A speciﬁc T cells responses. BALB/c mice were infected with Hh and 5 weeks later immunised with Ad85A. Controls were uninfected naïve or uninfected
Ad85A-immunised animals. Lung and splenic lymphocytes were isolated 4 weeks post immunisation. (A) Frequencies of CD44hi CD62Llo effector memory T cells among
splenic CD8+ and CD4+ T cells and representative ﬂow-cytometry staining gated on live CD45+ CD3+ CD8+ T cells. (B) Absolute numbers of lung leukocytes and frequencies of
l D8+ an
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t
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t
Hung  CD8+ and CD4+ T cells among total CD45+ cells. (C) Frequency of lung of lung C
 h in vitro stimulation with 85A peptides. Data points represent individual mice a
ukey’s post-test.
reviously been reported to induce a strong CD8 but weaker CD4T
ell response [13,15] and both Hh-infected and uninfected con-
rol mice show a similar increase in the frequency of CD8+ effector
emory T cells in the spleen following immunisation (Fig. 3A). In
he lungs, the total number of leukocytes is similar in control and
h-infected mice immunised with Ad85A and the frequencies ofd CD4+ T cells expressing IFN and TNF determined by ﬂow-cytometry following
izontal bars represent medians. * p < 0.05 as determined by one-way ANOVA with
CD4 and CD8 cells are unchanged (Fig. 3B). However, while in unin-
fected mice immunised with Ad85A, 4–5% of CD8 and ∼0.2% of CD4
lung T cells produce IFN and TNF upon antigenic restimulation
with 85A peptides, 85A-speciﬁc CD8T cell IFN responses are sig-
niﬁcantly reduced in immunised mice that have been previously
infected with Hh (Fig. 3C).
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Taken together, these results indicate that Hh infection of neona-
al BALB/c mice increases the lung mycobacterial load after Mtb
hallenge. Furthermore, Hh infection reduces antigen speciﬁc lung
mmune responses after Ad85A i.m. immunisation and abolishes
rotection against Mtb  challenge.
.3. IL10 is a key determinant of the Hh-mediated suppression of
d85A vaccine-induced protection against Mtb  challenge
IL10 plays a key role in preventing pathological intestinal
nﬂammation induced by Hh [10–12] and IL10−/− mice infected
ith Hh develop severe inﬂammation in the caecum and colon.
n contrast, Hh-infected wild-type mice mount an antigen-speciﬁc
egulatory T cell response to the bacterium that prevents bacteria-
nduced colitis in an IL10-dependent manner [16]. We  therefore
xamined the expression of Il10 mRNA in the colon and lungs of
aive and Hh-infected mice. We  ﬁrst conﬁrmed that Hh-infected
nimals are similarly colonised by Hh eight weeks after their ini-
ial infection (Fig. 4A). Both unimmunised and Ad85A-immunised
ice infected with Hh display signiﬁcantly up-regulated IL10 mRNA
xpression levels in the colon but not the lungs (Fig. 4B), with a
rend towards reduced T-bet and GATA3 mRNA expression, tran-
cription factors associated with Th1 and Th2 cell differentiation,
espectively (Fig. 4C). However, Hh infection does not affect Foxp3
issue expression level (Fig. 4D) or the frequency of Foxp3+CD4+
egulatory T cells in the colon, lung, spleen and mesenteric lymph
odes (Fig. 4E) in Ad85A-immunised mice.
Because IL10 has been shown to play an important role in reg-
lating immunity to Mtb  infection [17], we investigated whether
his pathway was involved in the Hh-mediated abrogation of
arenteral Ad85A-induced protection. We  therefore assessed the
ffect of IL10R signalling blockade during Mtb  challenge in con-
rol, uninfected immunised or Hh-infected immunised mice, using
 treatment regime shown capable of inducing colitis in normal
ice infected with Hh [16]. Anti-IL10R treatment of unimmunised
aive mice does not alter lung Mtb  CFU numbers, nor does it affect
rotection in uninfected mice immunised with Ad85A (Fig. 4F).
owever, the protective effect of Ad85A is restored in Hh-infected
ice treated with anti-IL10R, strongly suggesting that IL10 is a cru-
ial determinant of the Hh-mediated suppression of Ad85A vaccine
rotection against Mtb  challenge.
. Discussion
BCG has long been known to vary in efﬁcacy in different geo-
raphical locations, an effect often ascribed to exposure to EM [18].
s many candidate TB vaccines are now entering clinical trials [19],
t will be important to determine whether these will also show
ariable efﬁcacy in different locations and whether this variabil-
ty is linked to EM exposure only or reﬂects larger differences in
he gut microbiota composition across populations. Understanding
he mechanisms underlying variable vaccine efﬁcacy may  allow the
evelopment of strategies to overcome it.
Experimentally, parenteral administration of EM to mice does
ot affect protection induced by subunit vaccines (ESAT-6 or
g85B-ESAT-6 proteins), also administered parenterally [3]. In
ontrast, concurrent oral administration of EM or BCG abrogates
rotection induced by the parenterally administered subunit vac-
ine, Ad85A [4]. That oral but not parenteral administration of
M affects protection is in agreement with recent observations
ndicating the importance of the intestinal microbiota in both,
evelopment of the immune system and immune regulation.
In germ free mice most populations of lymphocytes are greatly
educed in number, while infection with host speciﬁc microbiota
eads to re-population of the immune system [20]. However, this is3 (2015) 1808–1814
not true of all lymphocyte populations; for example, CXCR6+ iNKT
cells are speciﬁcally increased in the colon and lung of germ free
mice, due to higher expression of CXCL16 at mucosal surfaces [21].
The link between intestinal and lung immunity is supported by
many other studies and manipulation of the microbiota by admin-
istration of a single bacterial species can greatly alter immune
responses. For example, monocolonisation of germ-free animals
with Bacteroides fragilis increases the induction of IL10-producing
Tregs [22]. Furthermore, there is an inverse relationship between
numbers of Foxp3+ Tregs and Th17 cells in the intestinal lamina
propria [23] and differentiation of Th17 cells, which are impor-
tant in protection against bacterial and fungal infections at mucosal
surfaces, is critically dependent on the presence of segmented ﬁl-
amentous bacteria in the intestine [24]. These data indicate that
production of two  cytokines, IL10 and IL17A that play important
roles in immunity to TB [17,25] is regulated by components of the
intestinal microbiota.
In other experiments, neonatal H. pylori infection of mice has
been shown to prevent the induction of lung allergic responses
through the reprograming of dendritic cells and induction of highly
suppressive Tregs in an IL10-dependant manner [8,26]. IL10 also
plays a key role in preventing the pathological colonic inﬂamma-
tion induced by infection with Hh [10–12], an effect attributed
mainly to the induction of Hh antigen-speciﬁc regulatory T cells
[16]. However, additional mechanisms may  be involved, since Hh
infection leads to its dominant presence among the local bacterial
pool and has been associated with a decreased overall diversity of
the intestinal micobiota [27].
Irrespective of whether the effect is directly attributable to Hh
itself, here we show that neonatal infection of BALB/c mice with
Hh up-regulates IL10 mRNA expression within the colonic lam-
ina propria and increases susceptibility to later Mtb  challenge, as
evidenced by higher lung Mtb CFU. Hh-infected mice immunised
parenterally with the recombinant subunit vaccine Ad85A further
display reduced protection against Mtb challenge compared to their
non-infected counterparts, an effect that is dependent on IL10R
signalling.
IL10 has been shown to modify protective immunity to sev-
eral organisms including Mtb. In Mtb infection there are two
main effects. Protection against infection is generally increased in
IL10 insufﬁcient mice and mycobacterial counts are lower. This is
thought to be mainly due to the effects of IL-10 on myeloid cells,
which become less responsive to IFN activation and therefore less
able to kill mycobacteria, while antigen presentation to T cells and
induction of Th17 responses are also inhibited. In contrast, IL10 may
dampen down Th1-mediated protective responses later in infec-
tion and lessen immune mediated pathology. However these effects
are both mouse and Mtb  strain dependent as well as subject to
environmental effects (reviewed in [17]).
In our experiments, Hh infection alone increases signiﬁcantly
Mtb lung CFU after challenge, a result in accord with the known
effects of IL10 on Mtb  infection. However, the abolition of parenteral
Ad85A-induced protection is much more surprising (Fig. 1B). The
exact mechanisms of this reduction of vaccine-induced protec-
tion remain to be determined, as there was no increase in lung
Il10 message. In an earlier study, protection induced by parenteral
but not intranasal administration of Ad85A was abolished by oral
administration of EM,  suggesting that priming of Ad85A speciﬁc
cells in peripheral lymph nodes or migration of cells into the lung,
rather than expression of local immunity, may  be affected. Recent
experiments on the effects of intestinal ﬂagellin-bearing bacte-
ria on systemic immune responses suggest that the mechanism
involves changes in myeloid cell function in lymph nodes [28]. Here
we show here that following parenteral immunisation, numbers of
antigen speciﬁc CD8+ T cells (the principal population induced by
Ad85A in BALB/c mice) in the lung are reduced in Hh infected mice.
I.C. Arnold et al. / Vaccine 33 (2015) 1808–1814 1813
Fig. 4. Protection against Mtb  challenge depends on IL10R signalling. Control or neonatally Hh-infected BALB/c mice were immunised with Ad85A and were compared to
unimmunised controls. (A) Hh colonisation levels quantiﬁed by SYBR qPCR (arbitrary units). (B–D) IL10, T-bet, GATA-3 and RORt mRNA expression of total colonic and lung
tissue  quantiﬁed by TaqMan qPCR and normalised to Hprt. (E) Frequencies of CD4+ CD25+ Foxp3+ regulatory T-cells among total live CD45+ cells in the colon, lungs, mesenteric
lymph nodes (MLNs) and spleen. Data are representative of or pooled from two  independent experiments. (F) Naive or Hh infected mice were immunised with Ad85A or left
unimmunised. Following challenge with Mtb, mice were treated with anti-IL10R mAb  or PBS on day 0, 7 and 17. Lung CFU were evaluated 5 weeks post challenge. Symbols
show  individual mice and horizontal lines indicate the means. ** p < 0.01, * p < 0.05 between the indicated groups as determine by Mann–Whitney U test (A–E) or one-way
ANOVA  with Tukey’s post-test (F).
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owever it remains to be determined whether this reduction is due
o impaired priming in systemic lymph nodes or if altered migration
s responsible.
Irrespective of the exact mechanisms involved, this is the
rst direct evidence that experimental Hh infection can pro-
oundly inﬂuence the magnitude and protective efﬁcacy of immune
esponses to Ad85A, a candidate TB vaccine, which has already
ntered clinical trials [29]. These data indicate that it may  be
xpected that not only BCG but subunit vaccines against TB will
uffer from geographical variation in efﬁcacy. Furthermore these
esults add to the arguments for further exploring the use of the
ulmonary route for administration of TB vaccines [30], since at
east under some circumstances this can overcome the suppressive
ffect of alterations in intestinal ﬂora [4].
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